Recommended Conferences

Genetic Engineering and Gene Therapy

Paris, France

Human Genetics and Genetic Disorders

Miami, USA

Tissue Engineering and Regenerative Medicine

Chicago, USA
Related Subjects
 

Immunogenicity of induced pluripotent stem cells

Author(s): Zhao T, Zhang ZN, Rong Z, Xu Y

Abstract

Induced pluripotent stem cells (iPSCs), reprogrammed from somatic cells with defined factors, hold great promise for regenerative medicine as the renewable source of autologous cells. Whereas it has been generally assumed that these autologous cells should be immune-tolerated by the recipient from whom the iPSCs are derived, their immunogenicity has not been vigorously examined. We show here that, whereas embryonic stem cells (ESCs) derived from inbred C57BL/6 (B6) mice can efficiently form teratomas in B6 mice without any evident immune rejection, the allogeneic ESCs from 129/SvJ mice fail to form teratomas in B6 mice due to rapid rejection by recipients. B6 mouse embryonic fibroblasts (MEFs) were reprogrammed into iPSCs by either retroviral approach (ViPSCs) or a novel episomal approach (EiPSCs) that causes no genomic integration. In contrast to B6 ESCs, teratomas formed by B6 ViPSCs were mostly immune-rejected by B6 recipients. In addition, the majority of teratomas formed by B6 EiPSCs were immunogenic in B6 mice with T cell infiltration, and apparent tissue damage and regression were observed in a small fraction of teratomas. Global gene expression analysis of teratomas formed by B6 ESCs and EiPSCs revealed a number of genes frequently overexpressed in teratomas derived from EiPSCs, and several such gene products were shown to contribute directly to the immunogenicity of the B6 EiPSC-derived cells in B6 mice. These findings indicate that, in contrast to derivatives of ESCs, abnormal gene expression in some cells differentiated from iPSCs can induce T-cell-dependent immune response in syngeneic recipients. Therefore, the immunogenicity of therapeutically valuable cells derived from patient-specific iPSCs should be evaluated before any clinic application of these autologous cells into the patients.

Similar Articles

Naive and primed pluripotent states

Author(s): Nichols J, Smith A

MicroRNAs: key regulators of stem cells

Author(s): Gangaraju VK, Lin H

Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse

Author(s): Stadtfeld M, Maherali N, Breault DT, Hochedlinger K

Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells

Author(s): Chan EM, Ratanasirintrawoot S, Park IH, Manos PD, Loh YH, et al.

Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution

Author(s): Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, et al.

Epigenetic memory in induced pluripotent stem cells

Author(s): Kim K, Doi A, Wen B, Ng K, Zhao R, et al.

Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells

Author(s): Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, et al.

Nuclear transfer to eggs and oocytes

Author(s): Gurdon JB, Wilmut I

CAF-1 is essential for heterochromatin organization in pluripotent embryonic cells

Author(s): Houlard M, Berlivet S, Probst AV, Quivy JP, Héry P, et al.

Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein

Author(s): Pivot-Pajot C, Caron C, Govin J, Vion A, Rousseaux S, et al.

Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors

Author(s): Jude CD, Climer L, Xu D, Artinger E, Fisher JK, et al.

Histone H4-K16 acetylation controls chromatin structure and protein interactions

Author(s): Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, et al.

Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs

Author(s): Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, et al.

Patient-specific induced pluripotent stem-cell models for long-QT syndrome

Author(s): Moretti A, Bellin M, Welling A, Jung CB, Lam JT, et al.

Modelling the long QT syndrome with induced pluripotent stem cells

Author(s): Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, et al.